Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 101–200 of 1,002
Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Systematic Review
Zhikang, Y., Li, C., & Zhai, S.-D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099044 · Cited by 106
“The AME and JAP CPGs were found in medical literature databases [23,25], and the others were found by Google searches.”
BackgroundMethodInfluentialAdane, E. D., Herald, M., & Koura, F. A. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1531 · Cited by 104
“Vancomycin exerts a time-dependent antibacterial effect,(9) and its clinical response is a function of the 24-hour area under the concentration-time curve to minimum inhibitory concentration (AUC:MIC) ratio.(10) A consensus review of the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Soc…”
BackgroundPullman, J. R., Gardovskis, J., Farley, B., Sun, E., Quintas, M., Lawrence, L. E., Ling, R., Cammarata, S., & PROCEED Study Group (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx329 · Cited by 104
Meng, L., Wong, T., Huang, S., Mui, E., Nguyen, V., Espinosa, G., Desai, J., Holubar, M. K., & Deresinski, S. C. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2234 · Cited by 104
Wong, G. Y. M., Sime, F. B., Lipman, J., & Roberts, J. A. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-288 · Cited by 124
“Methodologies for dose individualization based on calculation of individual pharmacokinetic parameters and PK/PD targets (AUC/MIC) are available but not widely adopted in clinical practice [103].”
BackgroundInfluentialHermsen, E. D., Hanson, M., Sankaranarayanan, J., Stoner, J. A., Florescu, M. C., & Rupp, M. E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903413514 · Cited by 102
“Thus, we chose to focus on the trough cut-point (15 mg/l) that is suggested inpracticeguidelines [5] andothermanuscripts,which facilitates comparisons to the published literature.”
BackgroundMethodResultInfluentialSmith, J. R., Roberts, K. D., & Rybak, M. J. (2015) · Infectious Diseases and Therapy · doi:10.1007/s40121-015-0077-7 · Cited by 106
“statement regarding its dosing [6].”
Self-citationAssessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients
Eiland, L. S., English, T. M., & Eiland, E. H. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p588 · Cited by 101
Clemens, E., de Vries, A., Pluijm, S. F. M., Zehnhoff‐Dinnesen, A. A., Tissing, W. J. E., Loonen, J. J., Broeder, E. V. D., Bresters, D., Versluys, B. A. B., Kremer, L. C. M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.023 · Cited by 100
“Vancomycin has been associated with ototoxicity in adults, mice and guinea pigs [17 e 20], but there have been no studies on this type of co-medication in childhood cancer survivors (CCSs).”
Cusumano, J. A., Klinker, K. P., Huttner, A., Luther, M. K., Roberts, J. A., & LaPlante, K. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa128 · Cited by 113
“aureus.(30) Therefore, if estimating AUC alone, vancomycin exposures will increase as the MIC increases (eg, if the reported MIC is 1.”
BackgroundInfluentialPotentials of nanotechnology in treatment of methicillin-resistant Staphylococcus aureus
Gao, Y., Chen, Y., Cao, Y., Mo, A., & Peng, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113056 · Cited by 107
Monteiro, J., Hahn, S. R., Gonçalves, J., & Fresco, P. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.420 · Cited by 96
“In children, an AUC/MIC of 400 correlates with a Ctrough of 11 mg/ L using a trapezoidal method to calculate AUC.35 For pediatric patients, monitoring of vancomycin Ctroughs is a recommendation stated in the summary of product characteristics and by several professional societies.3 During a study where vancomycin TDM…”
BackgroundInfluentialMeaney, C. J., Hynicka, L. M., & Tsoukleris, M. G. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1423 · Cited by 95
Antimicrobial Use at the End of Life Among Hospitalized Patients With Advanced Cancer
Thompson, A. J., Silveira, M. J., Vitale, C. A., & Malani, P. (2012) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909111432625 · Cited by 95
“Besides vancomycin-related toxicities (nephrotoxicity, ototoxicity, leukopenia, etc), excess use increases the risk of acquiring resistant organisms such as vancomycinresistant Enterococcus (VRE), as well as vancomycinintermediate and vancomycin-resistant S aureus (VISA and VRSA).(16) Although we did not specifically…”
BackgroundMethicillin-resistant Staphylococcus aureus (MRSA) in Iran: A systematic review and meta-analysis
Dadashi, M., Nasiri, M. J., Fallah, F., Owlia, P., Hajikhani, B., Emaneini, M., & Mirpour, M. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2017.09.006 · Cited by 96
“20 000 hospitalised US patients annually; this is similar to the number of deaths due to acquired immune deficiency syndrome (AIDS), tuberculosis and viral hepatitis combined [6].”
Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis
Arimura, Y., Yano, T., Hirano, M., Sakamoto, Y., Egashira, N., & Oishi, R. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.038 · Cited by 94
Minejima, E., Choi, J. J., Beringer, P. M., Lou, M., Tse, E., & Wong‐Beringer, A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00173-11 · Cited by 94
“Patients with 28-day mortality 9 (5) 7 (16) LOS after VAN initiation (median, IQR) 9 (7, 14)* 13 (10, 23)*”
BackgroundMcCreary, E. K., Kullar, R., Geriak, M., Zasowski, E. J., Rizvi, K., Schulz, L. T., Ouellette, K., Vasina, L., Haddad, F. A., Rybak, M. J., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz538 · Cited by 97
“However, each institution follows the general approaches recommended by the vancomycin use and monitoring guidelines and has pharmacist-driven pharmacokinetic services for the management of vancomycin therapy [36].”
BackgroundSelf-citationMoise, P. A., Amodio-Groton, M. I., Rashid, M., Lamp, K. C., Hoffman-Roberts, H., Sakoulas, G., Yoon, M., Schweitzer, S., & Rastogi, A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02192-12 · Cited by 93
“Vancomycin has served as the cornerstone of therapy for serious infections due to methicillin-resistant Staphylococcus aureus (MRSA) for 5 decades (3, 4).”
BackgroundRybak, M. J., Vidaillac, C., Sader, H. S., Rhomberg, P. R., Salimnia, H., Briski, L. E., Wanger, A. R., & Jones, R. N. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00448-13 · Cited by 94
“fections, such as complicated bacteremia (3, 8).”
BackgroundSelf-citationJohnson, J. D., Nessler, J. M., Horazdovsky, R. D., Vang, S. X., Thomas, A. J., & Marston, S. B. (2015) · The Journal of Arthroplasty · doi:10.1016/j.arth.2015.10.015 · Cited by 91
Casapao, A. M., Lodise, T. P., Davis, S. L., Claeys, K. C., Kullar, R., Levine, D. P., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03970-14 · Cited by 101
“We also examined the relationship between a Cmin 24 of 15 mg/liter and failure given the recent expert guidelines recommendations (7, 24).”
BackgroundMethodSelf-citationMoenster, R. P., Linneman, T. W., Finnegan, P. M., Hand, S., Thomas, Z., & McDonald, J. R. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12410 · Cited by 90
Chavada, R., Ghosh, N., Sandaradura, I., Maley, M. W., & van Hal, S. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02535-16 · Cited by 90
Prybylski, J. P. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1638 · Cited by 90
“2 Efforts to encourage practice to better reflect evidence culminated with the publication of a joint guideline from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists in 2009 that outlined best practices for adequate dosing…”
BackgroundDaptomycin: The role of high-dose and combination therapy for Gram-positive infections
Gould, I. M., Miró, J. M., & Rybak, M. J. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.05.005 · Cited by 93
Self-citationEckmann, C., & Dryden, M. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-12-554 · Cited by 89
Novel LC–MS/MS method for plasma vancomycin: Comparison with immunoassays and clinical impact
Oyaert, M., Peersman, N., Kieffer, D., Deiteren, K., Smits, A., Allegaert, K., Spriet, I., Eldere, J. V., Verhaegen, J., Vermeersch, P., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.12.012 · Cited by 89
Butterfield, J. M., Patel, N., Pai, M. P., ROSANO, T. G., Drusano, G. L., & Lodise, T. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01674-10 · Cited by 96
“While it is assumed that vancomycin is approximately 50% bound (25), protein binding for the agent has not been well characterized in the literature, and estimates have varied considerably (1, 2, 12, 18, 23, 31, 35).”
BackgroundKullar, R., Davis, S. L., Taylor, T. N., Kaye, K. S., & Rybak, M. J. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01017.x · Cited by 86
“The 2009 consensus guidelines on the therapeutic monitoring of vancomycin have recommended the use of higher doses of vancomycin for patients with complicated infections in order to achieve trough serum concentrations of 15– 20 mg/L to potentially improve clinical outcomes.(12) Although using higher doses of vancomyci…”
BackgroundMethodSelf-citationMoran, G. J., Abrahamian, F. M., LoVecchio, F., & Talan, D. A. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.11.050 · Cited by 89
Welte, T., & Pletz, M. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.045 · Cited by 94
“[45] RybakM, Lomaestro B, Rotschafer JC,Moellering Jr R, CraigW, BilleterM, et al.”
BackgroundInfluentialHaddad, N., Carr, M., Balian, S., Lannin, J., Kim, Y., Toth, C., & Jarvis, J. (2022) · Antibiotics · doi:10.3390/antibiotics11121843 · Cited by 96
Current Treatment Options for Acute Skin and Skin-structure Infections
Golan, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz004 · Cited by 84
“In addition, concentrations ≥10 mg/L are recommended to prevent development of bacterial strains resistant to vancomycin [33, 34].”
BackgroundAn Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults
Aljutayli, A., Marsot, A., & Nekka, F. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00866-2 · Cited by 85
Dalhoff, K., Abele‐Horn, M., Andreas, S., Deja, M., Ewig, S., Gastmeier, P., Gatermann, S. G., Gerlach, H., Grabein, B., Heußel, C. P., et al. (2018) · Pneumologie · doi:10.1055/s-0043-121734 · Cited by 97
Making the change to area under the curve–based vancomycin dosing
Heil, E. L., Claeys, K. C., Mynatt, R. P., Hopkins, T. L., Brade, K. D., Watt, I., Rybak, M. J., & Pogue, J. M. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp180034 · Cited by 86
Self-citationComparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
Estes, K. S., & Derendorf, H. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-12-533 · Cited by 82
Immune-mediated reactions to vancomycin
Minhas, J. S., Wickner, P. G., Long, A. A., Banerji, A., & Blumenthal, K. G. (2016) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2016.03.030 · Cited by 81
“To distinguish from red man syndrome and to be included in possible IgE-mediated HSR, cases of immediate reactions needed to have at least 1 of the following: (1) positive skin test result using a nonirritating concentration,9,10 (2) immediate symptoms consistent with anaphylaxis11 despite a red man syndrome protocol…”
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients
Póvoa, P. M. S. R., Moniz, P., Gonçalves-Pereira, J., & Coelho, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071401 · Cited by 91
“However, the susceptibility MIC profiles was associated with higher AUC/MIC ratios albeit with a limited distribution of lower values, possibly justifying the lack of statistical significance at the conventional breakpoint of 125 [114].”
BackgroundInfluentialSteinmetz, T., Eliakim‐Raz, N., Goldberg, E., Leibovici, L., & Yahav, D. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.04.003 · Cited by 90
“The average trough value over the duration of therapy was examined in four studies [11,32,36,38] and the initial trough value in 13 studies [11,34,35,37–40,43–46] (Choi et al.”
BackgroundInfluentialβ-lactam Therapeutic Drug Management in the PICU*
Cies, J. J., Moore, W. S., Enache, A., & Chopra, A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002817 · Cited by 95
Kingsley, J., Mehra, P., Lawrence, L. E., Henry, E., Duffy, E. M., Cammarata, S., & Pullman, J. R. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv411 · Cited by 80
Therapeutic drug monitoring for tomorrow
Eliasson, E., Lindh, J. D., Malmström, R. E., Beck, O., & Dahl, M. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1504-x · Cited by 85
“This led to a raised target interval for vancomycin serum concentrations, with recommended trough values of between 15 and 20 mg/L [23].”
BackgroundDownes, K. J., Hahn, A., Wiles, J. R., Courter, J. D., & Vinks, A. A. T. M. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.11.006 · Cited by 92
“Current clinical practice guidelines for the treatment of MRSA infections from the Infectious Diseases Society of America (IDSA) recommend dosing regimens that utilise this PK/PD target [52,53].”
BackgroundUse of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections
Giuliano, C. A., Haase, K. K., & Hall, R. G. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.123 · Cited by 91
Optimal Sampling Strategy Development Methodology Using Maximum A Posteriori Bayesian Estimation
van der Meer, A. F., Marcus, M. A. E., Touw, D. J., Proost, J. H., & Neef, C. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31820f40f8 · Cited by 78
Sakamoto, Y., Yano, T., Hanada, Y., Takeshita, A., Inagaki, F., Masuda, S., Matsunaga, N., Koyanagi, S., & Ohdo, S. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.02.025 · Cited by 77
“The clinical target range for VCM trough levels is 10–20 μg/ml (15–20 μg/ml for complicated infections), in which peak levels are found to be exceed 40–50 μg/ml (Rybak et al., 2009; Matzke et al., 1986).”
BackgroundFlannery, A. H., Bissell, B. D., Bastin, M. L. T., Morris, P. E., & Neyra, J. A. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004326 · Cited by 77
Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Holmes, N. E., Tong, S. Y. C., Davis, J. S., & van Hal, S. J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1397040 · Cited by 93
“1 μ g/ mL. 9,14,15 Conversely, the probability of target attainment is less likely in high vancomycin MIC infections and this has been the main rationale for alternative antimicrobial therapy in these situations.”
Roberts, J. A., Joynt, G. M., Choi, G. Y. S., Gomersall, C. D., & Lipman, J. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.11.002 · Cited by 85
Vandecasteele, S. J., Vriese, A. S. D., & Tacconelli, E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks495 · Cited by 83
Hirai, K., Ishii, H., Shimoshikiryo, T., Shimomura, T., Tsuji, D., Inoue, K., Kadoiri, T., & Itoh, K. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000346 · Cited by 76
Blevins, A., Lashinsky, J. N., McCammon, C., Kollef, M. H., Micek, S. T., & Juang, P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02658-18 · Cited by 78
Frazee, E. N., Rule, A. D., Herrmann, S. M., KASHANI, K. B., Leung, N., Virk, A., Voskoboev, N., & Lieske, J. C. (2014) · Critical Care · doi:10.1186/cc13899 · Cited by 75
“Using guideline recommendations, trough levels were all drawn immediately before the fourth dose of vancomycin to approximate steady-state conditions (4 to 5 half-lives) [4,5].”
BackgroundMethodInfluentialLo, Y. L., van Hasselt, J. G. C., Heng, S. C., Lim, C.-T., Lee, T.-C., & Charles, B. G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01370-09 · Cited by 75
“h (AUC24) to the MIC was at least 400 h (AUC24/MIC ratio of 400) (16, 28, 34).”
BackgroundVancomycin for Surgical Prophylaxis?
Crawford, T., Rodvold, K. A., & Solomkin, J. S. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis027 · Cited by 74
Tong, S. Y. C., Nelson, J., Paterson, D. L., Fowler, V. G., Howden, B. P., Cheng, A. C., Chatfield, M. D., Lipman, J., van Hal, S., O'Sullivan, M. V. N., et al. (2016) · Trials · doi:10.1186/s13063-016-1295-3 · Cited by 76
“Either vancomycin given IV dosed in accordance with the Australian Therapeutic Guidelines: Antibiotic version 15, 2014 [16] (15–20 mg/kg 12-hourly (q12h), preceded by a loading dose of 20–35 mg/kg if considered appropriate by the treating clinician) or the Infectious Diseases Society of America (IDSA) guidelines [57]…”
MethodBellos, I., Daskalakis, G., & Pergialiotis, V. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa184 · Cited by 73
Korposh, S., Chianella, I., Guerreiro, A. R., Caygill, S., Piletsky, S. A., James, S. W., & Tatam, R. P. (2014) · The Analyst · doi:10.1039/c3an02126b · Cited by 73
Ingram, P. R., Lye, D. C., Fisher, D. A., Goh, W.-P., & Tam, V. H. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.07.011 · Cited by 73
Vancomycin toxicity in neonates
Lestner, J. M., Hill, L. F., Heath, P. T., & Sharland, M. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000263 · Cited by 73
Penetration of Vancomycin into the Cerebrospinal Fluid: A Systematic Review
Beach, J. E., Perrott, J. L., Turgeon, R. D., & Ensom, M. H. H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0548-y · Cited by 73
Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice
Zamoner, W., Prado, I. R. S., Balbi, A. L., & Ponce, D. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13066 · Cited by 82
Laverdière, M., Bow, E. J., Rotstein, C., Autmizguine, J., Broady, R. C., Garber, G. E., Haider, S., Hussaini, T., Husain, S., Ovetchkine, P., et al. (2014) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2014/340586 · Cited by 75
“In clinical practice, therapeutic drug monitoring (TDM) is commonly performed in patients with bacterial infections and constitutes the standard of care for some antibiotics with a narrow therapeutic index such as vancomycin and the aminoglycosides (2,3).”
Pulido-Cejudo, A., Guzmán-Gutiérrez, M., Jalife-Montaño, A., Ortiz-Covarrubias, A., Martínez‐Ordaz, J. L., Noyola-Villalobos, H. F., & Hurtado‐López, L. M. (2017) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936117723228 · Cited by 74
Ramsey, A. C., & Staicu, M. L. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.11.012 · Cited by 71
Cheng, C., Liu, S., Xiao, D., Hollembaek, J., Yao, L., Lin, J., & Hansel, S. B. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.08.037 · Cited by 72
Chan, K. E., Warren, H. S., Thadhani, R., Steele, D., Hymes, J. L., Maddux, F. W., & Hakim, R. M. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010050 · Cited by 76
Mergenhagen, K. A., & Borton, A. R. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014546114 · Cited by 73
“Both accumulation of vancomycin in renal cells and alteration of mitochondrial function in the renal proximal tubule cells have been proposed as major factors in VAN.30,31 One study in rats indicated that daily doses of intravenous (IV) vancomycin 25 mg/kg caused a dose-dependent increase in elimination of tubule cell…”
BackgroundInfluentialWalraven, C. J., North, M., Marr-Lyon, L. R., Deming, P., Sakoulas, G., & Mercier, R.-C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr301 · Cited by 70
Läer, S., Barrett, J. S., & Meibohm, B. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337513 · Cited by 70
“64 Although there is controversy about the correlation between vancomycin serum concentrations and toxicity, 65,66 it has been suggested repeatedly that vancomycin trough concentrations are predictive for nephro toxicity.”
BackgroundWijesekara, P., Kumbukgolla, W. W., Jayaweera, J. A. A. S., & Rawat, D. S. (2017) · Veterinary Sciences · doi:10.3390/vetsci4010006 · Cited by 77
Friedel, M., Werbovetz, B., Drexelius, A., Watkins, Z., Bali, A., Plaxco, K. W., & Heikenfeld, J. C. (2023) · Lab on a Chip · doi:10.1039/d3lc00210a · Cited by 75
Chastre, J. E., Blasi, F., Masterton, R. G., Relio, J., Torres, A., & Welte, T. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12450 · Cited by 75
“However, continuous infusion vancomycin regimens are unlikely to improve patient outcome compared with intermittent dosing [132,133].”
BackgroundFactors Associated With Acute Kidney Injury in Children Receiving Vancomycin
Sinclair, E. A., Yenokyan, G., McMunn, A., Fadrowski, J. J., Milstone, A. M., & Lee, C. K. K. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014549185 · Cited by 69
“Nephrotoxicity associated with early vancomycin preparations was attributed to fermentation broth impurities, which are not present in contemporary preparations.(1,12,13) Use of contemporary preparations led to lower incidences of nephrotoxicity in adults, and early pediatric studies failed to demonstrate a risk of ne…”
BackgroundThe dosing and monitoring of vancomycin: what is the best way forward?
Drennan, P. G., Begg, E. J., Gardiner, S. J., Kirkpatrick, C. M. J., & Chambers, S. T. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.12.014 · Cited by 82
Kolluru, C., Williams, M., Yeh, J. S., Noel, R. K., Knaack, J. S., & Prausnitz, M. R. (2019) · Biomedical Microdevices · doi:10.1007/s10544-019-0363-3 · Cited by 71
Acute Kidney Injury During Vancomycin Therapy in Critically Ill Children
Totapally, B., Machado, J., Lee, H., Paredes, A. L., & Raszynski, A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1259 · Cited by 72
Horey, A., Mergenhagen, K. A., & Mattappallil, A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r158 · Cited by 68
García-de-la-Mària, C., Marco, F., Armero, Y., Soy, D., Moreno, A., del Río, A., Almela, M., Cervera, C., Ninot, S., Falces, C., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01011-09 · Cited by 68
“ventional dosing and are not safe in humans (20, 22, 25).”
BackgroundMethodInfluentialHara, G. L., Kanj, S. S., Pagani, L., Abbo, L. M., Endimiani, A., Wertheim, H. F. L., Amábile-Cuevas, C. F., Tattevin, P., Mehtar, S., Cardoso, F. L., et al. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.06.015 · Cited by 82
“It is mostly considered to be a time-dependent antibiotic [31], although some authors [32] suggest that an AUC/MIC > 400 is the target to achieve an optimal clinical response [33].”
BackgroundKufel, W. D., Seabury, R. W., Mogle, B. T., Beccari, M. V., Probst, L. A., & Steele, J. M. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz070 · Cited by 71
Hirai, K., Ihara, S., Kinae, A., Ikegaya, K., Suzuki, M., Hirano, K., & Itoh, K. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000270 · Cited by 67
Dalton, B., Rajakumar, I., Langevin, A., Ondro, C., Sabuda, D. M., Griener, T. P., Dersch‐Mills, D., & Rennert‐May, E. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.10.029 · Cited by 73
Model-Informed Precision Dosing of Antibiotics in Pediatric Patients: A Narrative Review
Abdulla, A., Edwina, A. E., Flint, R. B., Allegaert, K., Wildschut, E. D., Koch, B. C. P., & de Hoog, M. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.624639 · Cited by 71
Reuter, S. E., STOCKER, S. L., Alffenaar, J. C., Baldelli, S., Cattaneo, D., Jones, G. R. D., Koch, B. C. P., Kocic, D., Mathew, S. K., Molinaro, M., et al. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000944 · Cited by 72
Evaluation of Vancomycin Dosing Regimens in Preterm and Term Neonates Using Monte Carlo Simulations
Mehrotra, N., Tang, L. E., Phelps, S. J., & Meibohm, B. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01029.x · Cited by 65
Drug-Induced Kidney Injury in the Elderly
Khan, S. F., Loi, V., & Rosner, M. H. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0484-4 · Cited by 77
Vancomycin prescription in neonates and young infants: toward a simplified dosage
Oudin, C., Vialet, R., Boulaméry, A., Martin, C. M. P., & Simon, N. (2011) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/adc.2010.196402 · Cited by 64
Berthoin, K., Ampe, E., Tulkens, P. M., & Carryn, S. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.08.005 · Cited by 64
Peyko, V., Smalley, S., & Cohen, H. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016628960 · Cited by 64
Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
Stewart, C. L., Turner, M. S., Frens, J. J., Snider, C. B., & Smith, J. R. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0156-z · Cited by 68
“Vancomycin has been a mainstay of therapy for Gram-positive infections, especially MRSA, but long-term outpatient parenteral antimicrobial therapy (OPAT) with vancomycin is complicated due to frequent dosing and the need for therapeutic drug monitoring to prevent potential toxicities [6].”
BackgroundPompilio, A., Nicola, S. D., Crocetta, V., Guarnieri, S., Savini, V., Carretto, E., & Bonaventura, G. D. (2015) · BMC Microbiology · doi:10.1186/s12866-015-0449-x · Cited by 67
Acute Kidney Injury in Critically Ill Patients with Cancer
Benoît, D., & Hoste, E. A. J. (2009) · Critical Care Clinics · doi:10.1016/j.ccc.2009.09.002 · Cited by 66
Bogard, K., Peterson, N. T., Plumb, T. J., Erwin, M. W., Fuller, P. D., & Olsen, K. M. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206c3b2 · Cited by 63
“Recent guideline recommendations suggest more vigilant monitoring of vancomycin concentrations may be required to prevent treatment failures (40, 41).”
BackgroundMethodPark, K., Chong, Y. P., Kim, S., Lee, S., Choi, S., Lee, M. S., Jeong, J., Woo, J. H., & Kim, Y. S. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.07.026 · Cited by 63
Janssen, E. J. H., Välitalo, P. A. J., Allegaert, K., Cock, R. F. W. D., Simons, S. H. P., Sherwin, C. M. T., Mouton, J. W., van den Anker, J. N., & Knibbe, C. A. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01968-15 · Cited by 63
“Therefore, one could consider prolonging the infusion duration when a loading dose is given to reduce the risk of possible infusion reactions (17, 39).”
BackgroundResultInfluentialKarino, S., Kaye, K. S., Navalkele, B. D., Nishan, B., Salim, M., Solanki, S., Pervaiz, A., Tashtoush, N., Shaikh, H., Koppula, S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-15 · Cited by 63
“5 mg/dl or 50% increase from baseline, whichever was greater in at least 2 consecutive measurements during the period from the initiation of vancomycin therapy to 72 h after the completion of therapy (6).”
BackgroundMethodInfluentialSelf-citationTruong, J. Q., Levkovich, B., & Padiglione, A. A. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02459.x · Cited by 62
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.